PMA supplement
P830066 S009: ABBOTT IMX-CEA (LIST 3A33)
FDA PMA supplement · Normal 180 Day Track · Abbott Laboratories
Key facts
| Original PMA | P830066 |
|---|---|
| Supplement number | S009 |
| Supplement type | Normal 180 Day Track |
| Reason for the supplement | Change Design/Components/Specifications/Material |
| Trade name | ABBOTT IMX-CEA (LIST 3A33) |
| Generic name | SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN |
| Applicant | Abbott Laboratories |
| Product code | DHX |
| Received date | Jun 3, 1991 |
| Decision date | Jul 17, 1992 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: